Their $250K deals die in the meeting after Leah's: the homepage hero says "We build the systems to close that gap" while the button under it says "Give Today"... the champion forwards two companies, and the committee funds the cheaper one.
Your Doctor's Frame, armed. Time budget for a ~40-minute room: ~3 min small talk + the permission frame, ~12 min letting them map their own pain, ~10 min the ten-second proof + hypotheses, ~5 min the tolerance and timing pivot, ~10 min prescription + booking the next date.
Doctor's Frame from second one: ask permission to run a diagnostic instead of a pitch, praise the writing up front (it disarms the author in the room before any diagnosis touches her words), and spend exactly ONE homework flex. The permission ask sets the frame; the praise buys the right to be blunt later.
"Leah, Tamara... before we dive in, can I ask permission to treat this like a diagnostic instead of a pitch? I did my homework. I read your Brainspan piece, the Thrive launch post, the staff page, even your filings. The writing's strong and the conviction behind it is real. My hunch is the writing was never the problem. But hunches are cheap and you two have the actual data, so can I ask a few honest questions first... and then I'll tell you exactly what I see?"Run the second-room questions and the lost-deal autopsy, and qualify what the $250K actually is BEFORE any deal math (it's an inference, see the appendix). The goal is for Leah to say the diagnosis herself. She wrote this copy with her parents' mental-health story as the why... if you lecture, she defends the words; if she discovers it, she owns the reframe.
"Walk me through the last three partnership conversations that stalled. Did the comparison moment happen in the room with you, or afterward, when your contact took it inside to their board?"Screen-share their homepage and run the Three Questions Test: let them watch it fail on "who is it for" and "what problem," then concede it passes on POV... brain capital as economic infrastructure is their best asset, aimed at nobody. Then hand Tamara her own demo: ask ChatGPT live "what is Thrive, the AI women's health platform" and let the room watch Arianna Huffington's company come back. Findability plus narrative in one diagnosis; that thread is what turns the builder into a champion instead of a silent veto.
"Your hero says we build the systems. Your button says give today. Those are two different companies, and your buyer's committee resolves the contradiction by picking the cheaper one."Their 90 days is arithmetic, and the calendar does the persuading: day 90 lands mid-September, inside the fall planning cycle when corporate giving budgets for 2027 get shaped; October 10 is one year since Leah publicly announced Thrive under her own byline; November 11-13 is the Milken Future of Health Summit in DC. Then run the Voss tolerance question as the emotional pivot... whatever Leah names becomes the contract language and the Sprint's success criterion, said back in her words.
"You marked this very urgent... 90 days. What are you no longer willing to tolerate still being true on October 10?"Prescribe the Sprint against their own deadline symmetry: a 90-day rebuild for a self-declared 90-day window, partner-facing narrative landing in weeks 2-4 and going straight into live pitches. Book the next step before hangup: a 30-minute working session with Tamara to run the Thrive findability baseline. Within 24 hours, send a hosted recap link led by the homepage diagnosis and the ChatGPT Thrive screenshot... proof of diagnosis travels to Jorge López and the board better than a proposal ever will. A 90-day-urgent buyer who leaves without a date wasn't urgent.
"Would it be ridiculous to have the new story in partner meetings before that window closes?"The hero speaks infrastructure ("We build the systems to close that gap") and the button speaks charity ("Give Today"). The buyer meets two companies in five seconds and funds the cheaper story, anchoring against $0 (Yana's free tier... 15M+ reported users, LatAm-born) and ~$25K (a familiar sponsorship table). The "inferior alternatives" are the buyer's filing system working exactly as designed.
The site is wall-to-wall "we are committed / our mission / we believe." The CSR exec who must defend this check to a board never appears as protagonist, and neither does the young woman whose dropout gets prevented. Buyers fund stories that make them the hero; right now the foundation keeps that role for itself.
The least credible numbers sit in front (640x lifetime ROI, 6.79x SROI with no named evaluator) while the most credible assets sit buried: Vigil, del Río, an ex-McKinsey senior partner on the board, 700 scholarships actually delivered, the 1,000-engineer bench. No flagship story exists despite 1,000+ members. Competitors' proof is legible in five seconds; FDS's proof requires archaeology.
"Thrive" resolves in AI search to Arianna Huffington's Thrive Global (200+ organizations) and the Thrive AI Health venture backed by the OpenAI Startup Fund; "Brain Capital" is the Baker Institute's flag out of Houston, the same city as their phone number. The buyer who goes looking for FDS's proof literally gets handed a bigger player's proof instead.
Lead with the question, not your conclusion. Match what they say to one of these.
"Brain Capital infrastructure" arrives in the buyer's head with no bucket, so the brain grabs the nearest ones: wellness app (anchor price $0) or charity sponsorship (anchor ~$25K). Nobody has taught the buyer what a $250K Thrive partnership is a unit OF... the comparison problem lives in the missing category frame, and the named competitors are just where the buyer's brain lands by default.
The pipeline IS Leah: her 20-year network (World Bank, IDB, BHP-backed Fundación Chile) opens every door, then her champion goes inside to re-sell a committee she'll never meet, carrying a donor website as the only forwardable artifact. The committee refiles FDS as a charity and the deal gets "compared to inferior alternatives." A rolodex-fed pipeline caps at one person's calendar.
Since the May 28, 2026 CNBC story on the Common Sense Media + Stanford Brainstorm Lab report, the buyer's silent question is career risk: hero or headline. The same report rated Wysa... the clinically validated category leader... unacceptable for teens, while apps with licensed humans in the loop rated safe. FDS holds the best answer in the category (human-supervised, clinician-governed by Vigil and del Río) and it exists as a throwaway phrase in body copy instead of a named, auditable mechanism a CSR lead can hand their board. Unnamed safety is unprovable safety.
Thrive was announced October 2025 with a stated 10,000-women-in-a-year goal and is still "in development," with zero corporate anchor logos after 8 months. Leah announced a movement publicly, under her own byline, with her parents' story as the why... and the partnership revenue that funds it hasn't closed. Missing the window means missing it in public, in front of Jorge and the Jala empire. That's the thing she lies awake about.
| Prospect | Fundación del Saber (FDS) · fundaciondelsaber.org · self-described on the booking form as a "B2B Technology Company" |
| Structure | 501(c)(3) public charity, IRS-recognized Feb 2024, listed in Houston TX; Delaware incorporation per their own site; no Form 990 filed yet (too new), budget unverified |
| Parent / funding | Global philanthropic arm of Jorge López's Jala Group... López was an early Adobe employee and one of NetIQ's first ~15 people; 1,000+ Jalasoft engineers (mostly South America-based) sit behind FDS |
| HQ tell | The Calendly text number is the FDS switchboard, which sits inside Jalasoft's US footprint on Post Oak Blvd, Houston |
| In the room | Leah Pollak (CEO; wrote the current copy herself; 20-year public-private partnerships vet: World Bank, IDB, BHP-backed Fundación Chile, work across 35 countries; Duke + Georgetown) + Tamara Novakov (runs Thrive day to day; Purdue PhD in Mechanical Engineering, teaches business at UDD Chile) |
| The offer | Thrive... AI platform for young women's combined mental + hormonal health, "human oversight at every step"; announced Oct 10, 2025, still pre-launch ("currently in development"). Note: the women's-health page never names it "Thrive"... mirror whatever name Leah uses |
| Public goal | "Reach 10,000+ women within a year" (currently "1,000+ women as FDS members")... October 10, 2026 is one year since the Thrive announcement |
| Clinical bench | Dr. Pilar Vigil (PUC Chile professor since 1982, FACOG, 150+ publications, named Chile's most outstanding medical professional) + Dr. Juan Pablo del Río (IAP Young Physician Leader, 2021 cohort); board includes Alejandro Preusche, ex-McKinsey senior partner |
| Distribution / proof | Education-system and government partners in 20+ countries; 12,000+ members; 700+ scholarships delivered; zero corporate anchor logos on the partner wall |
| The wedge (verbatim) | "they compare us to inferior alternatives" |
| Urgency (self-reported) | "very urgent, need solution within 90 days" |
| Marketing spend (self-reported) | $10-20K/month |
| Ticket (inference) | ~$250K partnership ask... unverified; qualify on the call before any deal math |
| Their headline claims | 640x lifetime ROI; 6.79x SROI (evaluator unnamed)... quote-backs only, never endorse |
Walk in fluent in their market. Every number below was adversarially fact-checked (see the source-integrity appendix before quoting).
The buyer's rational hedge is three $80K checks to charities they already know: familiar names, zero headline risk, board-reportable. Backing a pre-launch AI tool that touches young women's mental health is career-risk concentrate post-CNBC... the champion's downside is a headline and the upside is invisible. FDS wins only when NOT acting becomes the riskier move: missing the board-reportable women's-health wave that McKinsey, WEF, and Milken legitimized. That risk-reversal story appears nowhere on their site.
Every flag they'd grab is already planted: Wysa leads its homepage with clinical validation (and still got rated unacceptable for teens in May... validation isn't safety), Yana owns free LatAm scale, Flo and Clue own "hormonal" in the buyer's head, Thrive Global plus the OpenAI-Startup-Fund-backed Thrive AI Health own the name, and the Baker Institute owns "Brain Capital." The category-of-one FDS CAN own is the narrow, fully verifiable sentence: clinician-governed early detection of combined mental and hormonal health for young women, engineered by a 1,000-person software group, distributed through education systems. You should be the one who shows them the difference between the broad claim that collapses in ten seconds of diligence and the narrow one nobody can copy... Tamara will stress-test the broad version and then discount everything else.
▸ Proof to drop (in order, don't fire all)
Their 90-day window and the Sprint's 90 days are the same number... use the symmetry. If the room stalls or the economic buyer turns out to be Jorge, fall to the scoped month-one diagnostic.
Sequenced so the partner-facing Thrive story lands in weeks 2-4 and goes straight into live pitches, inside their self-declared window. Scope: (1) the identity decision... which company is in the room when $250K is on the table, the foundation or the platform; (2) the MMF plus the proof spine: the narrow verifiable category claim, a named clinical-governance mechanism partners can hand their boards, one consented clinician-narrated flagship story, and a number ladder that puts auditable receipts before the bold modeling; (3) the Thrive naming and findability decision, teed up with live AI-search evidence; (4) the AI Brand Twin so Tamara's team tells the identical story when Leah isn't in the room. All four strategy lenses landed here independently.
If the room stalls on commitment or the economic buyer turns out to be Jorge, scope month one alone: the full diagnosis, the identity decision, and the partner-narrative spine delivered as a board-ready artifact Leah carries into the Jala room. It converts the build-the-case-for-Jorge motion into a paid deliverable instead of free homework, and it credits into the full Sprint when the board says yes.
The operating mode AFTER the rebuild, or the fallback if nonprofit budget mechanics genuinely can't clear a $13.5K monthly line without a board cycle. Say the order out loud if they ask: starting here puts a fractional engine under a broken narrative... wrong sequence. Quote $4,995 only; the $3,995 price expired June 1.
The ten-second demo they can't unsee: their own hero line ("We build the systems to close that gap") sitting above their own "Give Today" button, quoted verbatim on a screen share. Their words, their page, their contradiction.
The live ChatGPT pull: "what is Thrive, the AI women's health platform" returns Arianna Huffington's company. Findability plus narrative in one diagnosis... nobody else on their vendor list does both, and it's the thread that wins Tamara.
Fluency in THEIR clock: the fall budget-planning cycle their 90 days lands inside, the October 10 anniversary of the Thrive announcement, Milken in DC November 11-13. You walk in knowing their calendar better than they've articulated it themselves.
The bench recital from memory: Vigil (FACOG, 150+ publications), del Río (IAP Young Physician Leader), Preusche (ex-McKinsey), 1,000 Jala engineers, 20+ countries... followed by one question: why does none of it appear before the "Give Today" button?
The Doctor's Frame run clean: permission first, questions that let Leah say the diagnosis in her own words, the Voss tolerance pivot, prescription last. She wrote this copy from her parents' story... discovery makes her own the reframe, and lecture makes her defend the words.